化痰止咳合剂对AECOPD患者血清SAAIL-6IL-1β和肺功能的影响.PDFVIP

化痰止咳合剂对AECOPD 患者血清 SAA、IL-6、IL-1β和肺功能的影响 陈文霖，刘笑静(丽水市中医院，浙江 丽水 323000)  摘要：目的 研究化痰止咳合剂对慢性阻塞性肺疾病急性加重(acute exacerbations chronic obstructive pulmonary disease ， AECOPD) 患者血清淀粉样蛋白A(SAA) 、白介素-6(IL-6) 、白细胞介素-1β(IL-1β)和肺功能的影响。方法 将60 例AECOPD 患者按随机数字表法分为治疗组30 例与对照组30 例，2 组均予常规治疗，治疗组在此基础上加用化痰止咳合剂30 mL ， 每日3 次，共14 d，2 组均在治疗前后检测血清SAA、IL-1β、IL-6 、第1 秒用力呼气量/用力肺活量(FEV1/FVC) 、FEV1 占预计值百分比(FEV1%) ，采用临床COPD 问卷(clinical COPD questionnaire ，CCQ)调查临床症状改善情况。结果 治疗 前2 组患者血清清SAA、IL-1β、IL-6 、FEV1/FVC 及FEV1% 、CCQ 评分分值均无统计学差异(P0.05)；治疗后，与治疗 前比较，2 组患者血清SAA、IL-6 、IL-1β、肺功能、CCQ 评分值有统计学意义(P0.05)；与对照组比较，治疗组血清SAA、 IL-6 、IL-1β、CCQ 评分值差异有统计学意义(P0.05) ，2 组FEV1/FVC 、FEV1%差异无统计学意义(P0.05) 。结论 化痰 止咳合剂临床疗效确切，可抑制SAA、IL-6 、IL-1β水平及改善患者临床症状，其作用机制可能与其通过调节上述炎症因 子的表达而发挥降低气道炎症反应作用有关。 关键词：慢性阻塞性肺疾病急性加重；化痰止咳合剂；血清淀粉样蛋白A ；白介素-6；白介素-1β；肺功能 中图分类号：R969 文献标志码：B 文章编号：1007-7693(2017)03-0432-04 DOI: 10.13748/ki.issn1007-7693.2017.03.030 Clinical Study on the Effects of Huatan Zhike Mixture on the Levels of Serum SAA, IL-6, IL-1β and Lung Function in Acute Exacerbated Chronic Obstructive Pulmonary Disease Patients CHEN Wenlin, LIU Xiaojing(Traditional Chinese Medical Hospital of Lishui, Lishui 323000, China) ABSTRACT: OBJECTIVE To investigate the effect of Huatan Zhike mixture on the levels of serum SAA, IL-6, IL-1β and lung function in acute exacerbated chronic obstructive pulmonary disease(AECOPD) patients. METHODS Sixty patients with AECOPD were randomly assigned to the treatment group and the control group. All the patients were treated with routine western medical therapy and the patients in the treatment group were added with Huatan Zhike mixuture orally, with a course of 14 days. The changes of SAA, IL-6, IL-1β, the pulmonary functions and CCQ scores were evaluated before treatment and after